[1] |
ZHANG Lei, LYU Jian, XIE Yanming.
Efficacy and safety of Houpupaiqi Mixture in the treatment of postoperative lieus: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 799-806.
|
[2] |
CHENG Fengjingming, LYU Jian, XIE Yanming.
Efficacy and safety of compound salvia miltiorrhiza spray/aerosol for angina pectoris due to coronary artery disease: a Meta analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 536-543.
|
[3] |
SU Xinxin, LYU Jian, XIE Yanming.
Efficacy and safety of Toutongning capsules in the treatment of chronic headache: a Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 433-440.
|
[4] |
SUN Yixin, LIU Zhike, ZHAN Siyan.
Scoping review of near real-time surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 61-67.
|
[5] |
YU Ji, RAN Shuo.
Evaluation of drug use during applications of clinical pathways in patients with STEMI based on DUR and DUE
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 674-679.
|
[6] |
ZHANG Ruili, SU Shuang, JIANG Jiming, ZHANG Jing.
Thirty-six cases of adverse drug reactions/events caused by Xinhuang tablets
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 561-563.
|
[7] |
LI Yu, FAN Huihui, FENG Xiaojun, ZHANG Yonghuang, CHEN Qin, WANG Yunhong, CHEN Chuantao, ZHANG Lei, SHI Tianlu.
Association between ABCB1 C3435T polymorphisms and methotrexate-induced toxicity in childhood acute lymphoblastic leukemia: Meta analysis
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 421-425.
|
[8] |
HUANG Li, WEI Long, LI Hemei, YI Dan.
Literature review of 58 cases of adverse drug reactions induced by flurbiprofen
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 436-440.
|
[9] |
LI Xinxu, TANG Zhimin, ZHOU Jun, TAN Mingmin, LU Mingliang, WANG Jingzhao, WANG Jun.
Common questions about statistics in communication between drug sponsors and regulators in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 169-175.
|
[10] |
SHA Mingquan, ZHANG Yawei, ZHOU Hongjie, WEN Baoshu.
A comparative progress and prospect for drug technological guidances system in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1045-1049.
|
[11] |
SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu.
Research and reflection on regulatory science developments of U.S. FDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
|
[12] |
LI Lan, KONG Fanyao, ZHU Ying, SHEN Lu.
Developments and Suggestions on Cosmetics Adverse Reaction Monitoring in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 850-854.
|
[13] |
LIU Bo, WANG Xue, GUAN Shaochen, AN Moran, MU Yajie, YU Haixia, LI Yonglin, ZHANG Yatong.
Adverse Reactions of Lianhua Qingwen Capsules/Granules: A Systematic Review and Meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 864-868.
|
[14] |
XIA Lin, YANG Hongwen, WANG Fang.
Literature Analysis of Adverse Drug Reactions Induced by Articaine as Stomatological Medicine
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 160-163.
|
[15] |
JU Shan, LIU Yinghui, WANG Yawen, TENG Yingying, JIANG Yan, DENG Gang, SUN Lei.
Clinical Evaluation of Medical Devices Seen from International Coordination Documents
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1062-1065.
|